Histudy is a education website template. You can customize all.
Alzheimer’s disease, alternatively named senile dementia, is a progressive neurodegenerative disease that affects 55 million people worldwide. As of this moment, the disease has no cure, with treatments being targeted towards the symptoms; specifically, slowing down clinical decline. Important treatments called Aβ immunotherapies are being developed right now. Due to the severity of this disease, efficiently researching and quickly finding cures that are effective is crucial. This paper will be focused on reviewing current passive Aβ immunotherapies and determining the effectiveness through the immunotherapy's effects on amyloid plaque concentration and clinical decline. Through this, it can be determined if research on further passive Aβ immunotherapies is warranted. Through reviewing numerous studies and cases from multiple hospitals and institutions, it is found that Donanemab and Lecanemab are effective, with both being shown to reduce clinical decline and amyloid plaque concentration. Crenezumab is shown to have potential, with further studies required to confirm efficacy. The other three immunotherapies, Bapineuzumab, Ponezumab, and Gantenerumab, were found to be ineffective lowering amyloid plaque and slowing clinical decline. Future research should focus on further studying the efficacy and safety of these passive immunotherapies. Through these results, further research on passive Aβ immunotherapies is warranted, and should be focused on in the future. Using these findings, the route in which further research on passive Aβ immunotherapies can be determined and be as efficient as possible.
By Rithwik Tamilselvan